All In Biotech

Drug Trial Radar · NCT02115204

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes

Last checked: Nov 19, 2026Latest source record: Oct 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,011 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,011

Actual

Start

Jun 2000

Primary completion

Aug 2005

Study completion Aug 2010

Sponsor

Lead sponsor
Women's Cancer Study Group GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AGO Germany
First posted
Apr 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German Study Group and "Arbeitsgemeinschaft Gynäkologische Onkologie" (WSG-AGO) EC-Doc is a large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3 involved lymph nodes (LN).

Conditions

  • Breast Cancer

Interventions

  • EpirubicinDrug

  • CyclophosphamideDrug

  • DocetaxelDrug

  • MethotrexateDrug

  • 5-fluorouracilDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of event-free survivalTime frame: 60 months after end of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ev. Hospital Bethesda

    Mönchengladbach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.